Search for: All records

Abstract The brain has long been conceptualized as a network of neurons connected by synapses. However, attempts to describe the connectome using established network science models have yielded conflicting outcomes, leaving the architecture of neural networks unresolved. Here, by performing a comparative analysis of eight experimentally mapped connectomes, we find that their degree distributions cannot be captured by the well-established random or scale-free models. Instead, the node degrees and strengths are well approximated by lognormal distributions, although these lack a mechanistic explanation in the context of the brain. By acknowledging the physical network nature of the brain, we show that neuron size is governed by a multiplicative process, which allows us to analytically derive the lognormal nature of the neuron length distribution. Our framework not only predicts the degree and strength distributions across each of the eight connectomes, but also yields a series of novel and empirically falsifiable relationships between different neuron characteristics. The resulting multiplicative network represents a novel architecture for network science, whose distinctive quantitative features bridge critical gaps between neural structure and function, with implications for brain dynamics, robustness, and synchronization. 

Identifying novel drug-target interactions is a critical and rate-limiting step in drug discovery. While deep learning models have been proposed to accelerate the identification process, here we show that state-of-the-art models fail to generalize to novel (i.e., never-before-seen) structures. We unveil the mechanisms responsible for this shortcoming, demonstrating how models rely on shortcuts that leverage the topology of the protein-ligand bipartite network, rather than learning the node features. Here we introduce AI-Bind, a pipeline that combines network-based sampling strategies with unsupervised pre-training to improve binding predictions for novel proteins and ligands. We validate AI-Bind predictions via docking simulations and comparison with recent experimental evidence, and step up the process of interpreting machine learning prediction of protein-ligand binding by identifying potential active binding sites on the amino acid sequence. AI-Bind is a high-throughput approach to identify drug-target combinations with the potential of becoming a powerful tool in drug discovery. 

Abstract The increased complexity of infrastructure systems has resulted in critical interdependencies between multiple networks—communication systems require electricity, while the normal functioning of the power grid relies on communication systems. These interdependencies have inspired an extensive literature on coupled multilayer networks, assuming a hard interdependence, where a component failure in one network causes failures in the other network, resulting in a cascade of failures across multiple systems. While empirical evidence of such hard failures is limited, the repair and recovery of a network requires resources typically supplied by other networks, resulting in documented interdependencies induced by the recovery process. In this work, we explore recovery coupling, capturing the dependence of the recovery of one system on the instantaneous functional state of another system. If the support networks are not functional, recovery will be slowed. Here we collected data on the recovery time of millions of power grid failures, finding evidence of universal nonlinear behavior in recovery following large perturbations. We develop a theoretical framework to address recovery coupling, predicting quantitative signatures different from the multilayer cascading failures. We then rely on controlled natural experiments to separate the role of recovery coupling from other effects like resource limitations, offering direct evidence of how recovery coupling affects a system’s functionality. 

The COVID-19 pandemic has highlighted the need to quickly and reliably prioritize clinically approved compounds for their potential effectiveness for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs experimentally screened in VeroE6 cells, as well as the list of drugs in clinical trials that capture the medical community’s assessment of drugs with potential COVID-19 efficacy. We find that no single predictive algorithm offers consistently reliable outcomes across all datasets and metrics. This outcome prompted us to develop a multimodal technology that fuses the predictions of all algorithms, finding that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We screened in human cells the top-ranked drugs, obtaining a 62% success rate, in contrast to the 0.8% hit rate of nonguided screenings. Of the six drugs that reduced viral infection, four could be directly repurposed to treat COVID-19, proposing novel treatments for COVID-19. We also found that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these network drugs rely on network-based mechanisms that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.